CapsoVision submits 510(k) to FDA for AI-assisted reading module for CapsoCam Plus

CapsoVision, Inc

Submitted 510(k) to FDA for proprietary AI-assisted module for CapsoCam Plus capsule endoscopy system.
AI module designed to improve detection of clinically significant pathology and reduce clinician review time.
Company plans to commence U.S. commercialization following FDA clearance.
CapsoVision claims it is the only capsule endoscopy company with in-house AI core competency.
Cloud-based architecture eliminates need for on-site servers, reducing cost and IT maintenance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.